newsfilter
← Latest News
Earnings Call Transcripts·

RNAi Roundtable: ALN-6400, Targeting Plasminogen to Address Rare Bleeding Disorders - Alnylam Pharmaceuticals, Inc.

Good morning, everyone. I'm Chris Brickley, Director of Investor Relations at Alnylam, and I'm pleased to be kicking off our 10th RNAi Roundtable series this morning. Throughout these events, we aim to highlight a few of